Company Profile

mBio Diagnostics Inc
Profile last edited on: 6/28/2018      CAGE: 5WYW2      UEI: HMBEH3F1D7T3

Business Identifier: Rapid point-of-care diagnostics and on-the-spot sample testing
Year Founded
2009
First Award
2006
Latest Award
2022
Program Status
Active
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

5603 Araphoe Avenue Suite 1
Boulder, CO 80303
   (303) 952-2905
   info@mbiodx.com
   www.mbiodx.com
Location: Single
Congr. District: 02
County: Boulder

Public Profile

MBio Diagnostics, Inc. is a clinical diagnostics and life sciences technology company developing a suite of simple, multiplexed diagnostic tests using its proprietary LightDeckTM technology. Initial product development had focused on high impact infectious diseases to include HIV, hepatitis, and influenza. The company’s product development had aimed at decentralized testing, from the clinic to the home. To that end, the firm has develops a suite of multiplexed diagnostic tests with products now including CD4 System, which provides CD4 T helper cell counts at the point-of care; and MBio Array, a multiplexed fluorescence immunoassay system that provides the simultaneous measurement of multiple analytes from a sample. The company products are based on LightDeck, a fluorescence assay illumination method and variation on planar waveguide technology used for performing sensitive biological assays enabling expansion to rapid CD4 cell counting, and hepatitis and syphilis co-infection testing applications.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
20-24
Revenue Range
2M-2.5M
VC funded?
Yes
Public/Private
Privately Held
Stock Info
----
IP Holdings
15-19

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 1 USDA $174,508
Project Title: Detection of Per- and Polyfluorinated Substances
2020 2 NIH $1,170,660
Project Title: Point-of-Care Prognostic Tool for Sepsis
2020 1 NIH $149,900
Project Title: Rapid Detection of Legionella in Enironmental Samples with Speciation and Serotyping
2019 2 USDA $696,027
Project Title: Rapid, Multiplexed Detection of Algal Toxins in Shellfish
2017 1 DARPA $149,503
Project Title: Point of Care Host-Pathogen Monitoring System

Key People / Management

  Christopher John Myatt -- Founder and CEO

  Sarah Bickman -- Director of Water and Veterinary Products

  John Dunn -- Production Manager

  Sarah C (Sally) Hatcher -- Former President

  Michael J Lochhead -- Executive Vice President and Chief Technology Officer

  Mike J Lochhead -- Vice President

  Michael Seely -- Media Contact

  Nick Traggis -- Nick Traggis 3rd degree connection 3rd VP of Business Development